Abstract
Background NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults.
Methods This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised two intramuscular injections, 21 days apart. Primary outcomes were reactogenicity, safety labs, and immunoglobulin G (IgG) anti-spike protein response. Secondary outcomes included adverse events, wild-type virus neutralizing antibody, and T-cell responses.
Results Participants received NVX-CoV2373 with or without Matrix-M1 (n=106) or placebo (n=25). There were no serious adverse events. Reactogenicity was mainly mild in severity and of short duration (mean ≤2 days), with second vaccinations inducing greater local and systemic reactogenicity. The adjuvant significantly enhanced immune responses and was antigen dose-sparing, and the two-dose 5μg NVX-CoV2373/Matrix-M1 vaccine induced mean anti-spike IgG and neutralizing antibody responses that exceeded the mean responses in convalescent sera from COVID-19 patients with clinically significant illnesses. The vaccine also induced antigen-specific T cells with a largely T helper 1 (Th1) phenotype.
Conclusions NVX-CoV2373/Matrix-M1 was well tolerated and elicited robust immune responses (IgG and neutralization) four-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype. These findings suggest that the vaccine may confer protection and support transition to efficacy evaluations to test this hypothesis. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).
Competing Interest Statement
Cheryl Keech, Gary Albert, Patricia Reed, Susan Neal, Joyce Plested, Mingzhu Zhu, Shane Cloney-Clark, Xaixia Zhou, Nita Patel, Iksung Cho, Andreana Robertson, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Bethanie Wilkinson, Gale Smith and Gregory Glenn are employees of Novavax, Inc. Matthew Frieman, Robert Haupt, James Logue, Marisa McGrath, and Stuart Weston are researchers at the University of Maryland School of Medicine and received a grant from Novavax. Pedro Piedra is a researcher at Baylor University and received non-financial support/materials transfer agreement for spike protein of SARS-Cov-2 and ACE2. Jason Lickliter is an employee of Nucleus Network Pty Ltd and the institution received funding from Novavax to support operation of the clinical trial. Paul Griffin is an employee of Q-Pharm, which was contracted by Nucleus to conduct the clinical trial.
Clinical Trial
NCT04368988
Funding Statement
Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Alfred Hospital Ethics Committee, EC services, 55 Commercial Rd, Melbourne VIC 3004
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
These are interim data, and individual participants remain masked to individual vaccine assignment. Therefore, it would be inappropriate to share individual level results at this time.
